VXRT - Vaxart's Oral COVID-19 Vaccine Could Be A 2021 Biotech Highlight

• Vaxart has been developing its oral COVID-19 vaccine since early January 2020 and I broadly agree analyst consensus price target of $17.70.
• The company has - surprisingly - few rivals in this space and the logic of developing an oral COVID-19 vaccine is sound. Easier distribution, cost effective and patient friendly.
• I'm curious as to why Vaxart has not been able to find a development partner for its COVID-19 or its Influenza vaccines.
• The data appear to check out on both fronts so far. Logic seems to suggest that if Vaxart is able to fund a pivotal trial, it would likely secure an approval.
• Vaxart shares traded at $17 last July on news it had joined Operation Warp Speed. When this proved false shares collapsed, I wonder if they should really have gained.

For further details see: